Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNicos Karasavvasen_US
dc.contributor.authorChitraporn Karnasutaen_US
dc.contributor.authorHathairat Savadsuken_US
dc.contributor.authorSirinan Madnoteen_US
dc.contributor.authorDutsadee Inthawongen_US
dc.contributor.authorSomsak Chantakulkijen_US
dc.contributor.authorSurawach Rittiroongraden_US
dc.contributor.authorSorachai Nitayaphanen_US
dc.contributor.authorPunnee Pitisuttithumen_US
dc.contributor.authorPrasert Thongcharoenen_US
dc.contributor.authorVinai Siriyanonen_US
dc.contributor.authorCharla A. Andrewsen_US
dc.contributor.authorSusan W. Barnetten_US
dc.contributor.authorJames Tartagliaen_US
dc.contributor.authorFaruk Sinangilen_US
dc.contributor.authorDonald P. Francisen_US
dc.contributor.authorMerlin L. Robben_US
dc.contributor.authorNelson L. Michaelen_US
dc.contributor.authorViseth Ngauyen_US
dc.contributor.authorMark S. De Souzaen_US
dc.contributor.authorRobert M. Parisen_US
dc.contributor.authorJean Louis Excleren_US
dc.contributor.authorJerome H. Kimen_US
dc.contributor.authorRobert J. O'Connellen_US
dc.description.abstract© Copyright 2015, Mary Ann Liebert, Inc. 2015. RV144 correlates of risk analysis showed that IgG antibodies to gp70V1V2 scaffolds inversely correlated with risk of HIV acquisition. We investigated IgG antibody responses in RV135 and RV132, two ALVAC-HIV prime-boost vaccine trials conducted in Thailand prior to RV144. Both trials used ALVAC-HIV (vCP1521) at 0, 1, 3, and 6 months and HIV-1 gp120MNgD and gp120A244gD in alum (RV135) or gp120SF2 and gp120CM235 in MF59 (RV132) at 3 and 6 months. We assessed ELISA binding antibodies to the envelope proteins (Env) 92TH023, A244gD and MNgD, cyclicV2, and gp70V1V2 CaseA2 (subtype B) and 92TH023 (subtype CRF01-AE), and Env-specific IgG1 and IgG3. Antibody responses to gp120 A244gD, MNgD, and gp70V1V2 92TH023 scaffold were significantly higher in RV135 than in RV132. Antibodies to gp70V1V2 CaseA2 were detected only in RV135 vaccine recipients and IgG1 and IgG3 antibody responses to A244gD were significantly higher in RV135. IgG binding to gp70V1V2 CaseA2 and CRF01-AE scaffolds was higher with the AIDSVAX®B/E boost but both trials showed similar rates of antibody decline post-vaccination. MF59 did not result in higher IgG antibody responses compared to alum with the antigens tested. However, notable differences in the structure of the recombinant proteins and dosage used for immunizations may have contributed to the magnitude and specificity of IgG induced by the two trials.en_US
dc.subjectImmunology and Microbiologyen_US
dc.titleIgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimensen_US
article.title.sourcetitleAIDS Research and Human Retrovirusesen_US
article.volume31en_US Forces Research Institute of Medical Sciences, Thailanden_US Universityen_US Mai Universityen_US RESOURCES INTERNATIONAL, INC.en_US VACCINES AND DIAGNOSTICS, INC.en_US Pasteuren_US Solutions for Infectious Diseasesen_US Reed Army Institute of Researchen_US Vaccine Institute, Seoulen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.

Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.